A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors

Med Chem. 2010 Nov;6(6):374-87. doi: 10.2174/157340610793563992.

Abstract

Starting from a previously reported lead compound GR30040X (a hydantoin tetrahydro-β-carboline derivative with a 4- pyridinyl ring at C- 5), a series of structurally related tetrahydro-β-carboline derivatives were prepared. The tetrahydro-β-carboline skeleton was fused either to a hydantoin or to a piperazindione ring, the pendant aryl group attached to C-5 or C-6 was changed to a 3, 4-dimethoxyphenyl or a 3-pyridinyl ring; different N-substituents on the terminal ring were introduced, a straight chain ethyl group, a branched tert. butyl and P-chlorophenyl group rather than n-butyl group of the lead compound. All four possible diastereomers of target tetrahydro-β-carboline derivatives were prepared, separated by column chromatography and the significance of these stereochemical manipulations were studied. Synthesized compounds were evaluated for their inhibitory effect versus PDE5. Seven hits were obtained with appreciable inhibitory activity versus PDE5 with IC₅₀s 0.14 - 4.99 µM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbolines / chemical synthesis*
  • Carbolines / chemistry
  • Carbolines / pharmacology
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / chemistry
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism
  • Humans
  • Inhibitory Concentration 50
  • Phosphodiesterase 5 Inhibitors / chemical synthesis*
  • Phosphodiesterase 5 Inhibitors / chemistry
  • Stereoisomerism
  • Structure-Activity Relationship
  • Tadalafil

Substances

  • Carbolines
  • GR30040X compound
  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
  • Cyclic Nucleotide Phosphodiesterases, Type 5